Histamine and hrh1 signaling activity as biomarkers and associated methods

Abstract

A method of determining the likelihood that a subject with cancer will respond to an immunotherapy comprising a checkpoint inhibitor. The method comprises detecting the level of histamine in a biological sample obtained from the subject. Subjects determined to have a low likelihood of responding …